Evidence map›Paper›PMID 41051138›Full record

ArticleClinical and translational science2025

Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives.

Tamás Sass, Judit P Szabó, Renáta Adél Dienes, Péter Árkosy, Gábor Opposits, István Jószai, Anikó Fekete, Ferenc Fenyvesi, István Hajdu, György Trencsényi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tamás SassDepartment of Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0009-0004-8610-0682
Judit P SzabóDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0002-0066-5745
Renáta Adél DienesGyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0009-0003-8225-752X
Péter ÁrkosyDepartment of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0009-0001-2224-2903
Gábor OppositsDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0002-0065-224X
István JószaiDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0002-1940-3390
Anikó FeketeDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0002-0951-6092
Ferenc FenyvesiDepartment of Molecular and Nanopharmaceutics, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.ORCID 0000-0003-2890-0783
István HajduDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0001-8008-7756
György TrencsényiGyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0001-6456-6212
Zita KépesGyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0003-2889-8521

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the increasing incidence and mortality of breast cancer, the development of target-specific imaging probes for early disease detection seems straightforward. Prostaglandin E2 (PGE2) and its receptors have a crucial role in tumor angiogenesis; therefore, radiolabelled cyclodextrins targeting such biomolecules may serve as selective vectors for positron emission tomography (PET) imaging of breast cancer. Herein, we aimed to monitor PGE2 production in MDA-MB-HER2-positive and 4 T1 triple-negative breast cancer xenografts using

Indexed as

Breast NeoplasmsCyclodextrinsPositron-Emission TomographyRadiopharmaceuticalsAcetatesAnimalsbeta-CyclodextrinsCell Line, TumorFemaleGallium RadioisotopesHumansMiceMice, SCIDTissue DistributionXenograft Model Antitumor AssaysAcetatesbeta-CyclodextrinsCyclodextrinsGallium-68Gallium RadioisotopesRadiopharmaceuticalsangiogenesisbreast cancercyclodextrinpositron emission tomographypreclinicalprostaglandin E2radiopharmaceuticals

Identifiers

PMID41051138
PMCPMC12498275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.